Drugs / MUBRITINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00034281 | Jun 2002 → Sep 2003 | breast neoplasm, kidney neoplasm, lung neoplasm, ovarian neoplasm +1 | Takeda | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUBRITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614707 ↗ |
| Known as | TAK-165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00034281 ↗ |
| Action | Inhibit | “TAK-165 is an active and selective inhibitor of tyrosine kinase activity of HER2” NCT00034281 ↗1“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1614707 ↗ |
| Modality | Small molecule | — CHEMBL1614707 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1614707 ↗ |